Pediatric Lymphoma Joins Family of BRCA2 Cancers Pediatric Lymphoma Joins Family of BRCA2 Cancers

Researchers call for genetic testing of all survivors of pediatric non-Hodgkin lymphoma after data revealed BRCA2 is implicated in the childhood disease.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Related Links:

Discussion In this section, we discuss the mechanisms responsible for lymphomagenesis in the various inborn errors of immunity and provide an overview of the treatment. Defects in Immune Responses That Predispose to Lymphomagenesis in PIDDs The complex immune mechanisms and their interplay that predisposes to neoplastic transformation of B or T cells and development of lymphomas in PIDD patients has not been fully elucidated. However, it is expected that the etiology in most cases is multifactorial and related to a dynamic regulation of immune response and environmental triggers (Figure 3). An underlying intrinsic susce...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions: CAR T cell therapies have demonstrated the clinical benefits of harnessing our body's own defenses to combat tumor cells. Similar research is being conducted on lesser known modifications and gene-modified immune cells, which we highlight in this review. Introduction Chimeric antigen receptors and engineered T cell receptors (based on previously identified high affinity T cell receptors) function by redirecting T cells to a predefined tumor-specific (or tumor-associated) target. Most of these modifications use retroviral or lentiviral vectors to integrate the construct, and most of the receptors ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
The first two authors and last two authors contributed equally.Genome-wide association studies (GWAS) have identified risk loci for Acute Lymphoblastic Leukemia (ALL), Chronic Lymphoblastic Leukemia (CLL) and Non-Hodgkin Lymphoma, however an Acute Myeloid Leukemia (AML) GWAS has not been published to date. We performed a GWAS to identify AML and Myelodysplastic Syndrome (MDS) risk loci using a nested case-control study design in the DISCOVeRY-BMT cohorts which includes almost 2000 AML and MDS patients as cases and 2813 unrelated donors as controls.Genotyping was performed using the Illumina Human OmniExpress BeadChip and i...
Source: Blood - Category: Hematology Authors: Tags: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Poster I Source Type: research
TRENTON, N.J. (CBS/AP) — U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults. The Food and Drug Administration allowed sales of the treatment from Kite Pharma. It uses the same technology, called CAR-T, as the first gene therapy approved in the U.S. in August, a treatment for childhood leukemia from Novartis Pharmaceuticals. That Novartis treatment was tested in Boston. In those tests, Dana Farber and Brigham and Women’s Hospital cancer researchers found that 80 percent of lymphoma patients who underwent the treatmen...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health Healthwatch Local News blood cancer Brigham and Women's Hospital Dana Farber FDA Gene Therapy Novartis Pharmaceuticals Source Type: news
CONCLUSION: Though ALK plays a role in prognostication of systemic ALCL, advanced stage disease and an inflammatory milieu may modulate the final outcome. We report a study of clinical and pathologic prognostic features in 102 cases of anaplastic large cell lymphoma (ALCL) from a cancer referral institute in India. Anaplastic lymphoma receptor tyrosine kinase (ALK-1) expression was seen in 71/102 (69.6%) cases and was not found to impact overall survival (OAS) or disease-free survival (DFS). The 2-year OAS rate for ALK-positive patients was 63.5% and DFS rate was 54.4%, while for ALK-negative patients, the OAS was 60.5% an...
Source: Indian Journal of Pathology and Microbiology - Category: Pathology Authors: Tags: Indian J Pathol Microbiol Source Type: research
oit Y Abstract Asparaginase is an essential component of combination chemotherapy for childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. The value of asparaginase was further addressed in a group of non-very high risk patients by comparing a prolonged (long-asparaginase) versus standard (short-asparaginase) native E.coli asparaginase treatment through a randomized question as part of the phase III 58951 trial of the European Organisation for Research and Treatment of Cancer Children's Leukemia Group. The main endpoint was disease-free survival. Overall, 1,552 patients were randomly assigned to long...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Abstract Therapy-related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) is a devastating late effect of cancer treatment. There is limited data on incidence of t-AML/MDS from India. We retrospectively studied pediatric t AML/MDS at our institute between January 1996 and December 2015. Among 1285 children, 8 patients developed t-AML with a median age of 15.5  years. Overall incidence of t-AML/MDS was 0.62% [0.99% (4/402) in solid tumours and 0.45% (4/883) in leukemia/lymphoma,P = 0.26] with 6390 patient years of follow up. Primary malignancy included sarcoma [bone (2), soft tissue (2)], B-non-H...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
Summary Cancer is increasingly important in low and middle‐income settings where infectious diseases are declining. Childhood cancers treated in well‐resourced centres have excellent outcomes with more than 80% survival. This success is not reflected in low‐income settings where challenges involve every step on the care pathway. Access to diagnosis, delayed presentation, advanced disease, co‐morbidities and underlying malnutrition make treatment difficult. Treatments are costly for impoverished families. Yet, the common haematological malignancies (Burkitt lymphoma, Hodgkin lymphoma, non Hodgkin lymphoma) are relat...
Source: British Journal of Haematology - Category: Hematology Authors: Tags: Review Source Type: research
CONCLUSIONS: Similar to previous studies, the total estimated effective doses in children with cancer have been found various according to diagnosis, stage and clinical course. To clarify the harmfull effects of radiation burden, prospective studies should be conducted in children with cancer. PMID: 27878779 [PubMed - as supplied by publisher]
Source: World Journal of Pediatrics : WJP - Category: Pediatrics Authors: Tags: World J Pediatr Source Type: research
illiams D, Woessmann W, Wrobel G, Pillon M Abstract Children and adolescents with pre-existing conditions such as DNA repair defects or other primary immunodeficiencies have an increased risk of non-Hodgkin's lymphoma. However, large-scale data on patients with non-Hodgkin's lymphoma and their entire spectrum of pre-existing conditions are scarce. In a retrospective multi-national study performed by means of questionnaires sent out to the national study groups or centres, the two largest consortia in childhood non-Hodgkin's lymphoma, the European Intergroup for Childhood non-Hodgkin's lymphoma and the internationa...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
More News: Cancer | Cancer & Oncology | Childhood Cancer | Genetics | Hematology | Hodgkin's Disease | Lymphoma | Non-Hodgkin's Lymphoma | Pediatrics